Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Stock Price & Overview
NASDAQ:FBIOP • US34960Q2084
Current stock price
14.42 USD
-0.01 (-0.07%)
Last:
The current stock price of FBIOP is 14.42 USD. Today FBIOP is down by -0.07%. In the past month the price increased by 3.67%. In the past year, price increased by 118.15%.
FBIOP Key Statistics
52-Week Range5.6 - 14.64
Current FBIOP stock price positioned within its 52-week range.
1-Month Range12.87 - 14.56
Current FBIOP stock price positioned within its 1-month range.
- Market Cap
- 464.324M
- P/E
- N/A
- Fwd P/E
- 1,413.73
- EPS (TTM)
- -0.88
- Dividend Yield
- N/A
FBIOP Stock Performance
Today
-0.07%
1 Week
+7.37%
1 Month
+3.67%
3 Months
+18.20%
Longer-term
6 Months +106.00%
1 Year +118.15%
2 Years -2.37%
3 Years -21.71%
5 Years -43.01%
10 Years N/A
FBIOP Stock Chart
FBIOP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to FBIOP. When comparing the yearly performance of all stocks, FBIOP is one of the better performing stocks in the market, outperforming 93.65% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
FBIOP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FBIOP. FBIOP may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
FBIOP Earnings
On March 31, 2026 FBIOP reported an EPS of -0.01 and a revenue of 16.08M. The company missed EPS expectations (-108.91% surprise) and missed revenue expectations (-39.76% surprise).
Next Earnings DateMay 13, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-$0.01
Revenue Reported16.079M
EPS Surprise -108.91%
Revenue Surprise -39.76%
FBIOP Forecast & Estimates
8 analysts have analysed FBIOP and the average price target is 62.02 USD. This implies a price increase of 330.12% is expected in the next year compared to the current price of 14.42.
For the next year, analysts expect an EPS growth of 101.16% and a revenue growth 31.26% for FBIOP
Analysts
Analysts82.5
Price Target62.02 (330.1%)
EPS Next Y101.16%
Revenue Next Year31.26%
FBIOP Financial Highlights
Over the last trailing twelve months FBIOP reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 73.09% compared to the year before.
Income Statements
Revenue(TTM)63.26M
Net Income(TTM)-1.88M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.01% | ||
| ROE | -3.78% | ||
| Debt/Equity | 1.19 |
Chartmill High Growth Momentum
EPS Q2Q%98.67%
Sales Q2Q%6.34%
EPS 1Y (TTM)73.09%
Revenue 1Y (TTM)9.69%
FBIOP Ownership
Ownership
Inst Owners18.23%
Shares32.20M
Float24.87M
Ins Owners15.69%
Short Float %0%
Short Ratio0.06
FBIOP Industry Overview
FBIOP operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.2%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.1
- Average Fwd P/E
- 22.4
- Average Debt/Equity
- 2.1
FBIOP Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.75 | 349.666B | ||
| AMGN | AMGEN INC | 14.8 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.06 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 24.944B | ||
| INCY | INCYTE CORP | 10.85 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FBIOP
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Company Info
IPO: 2011-11-17
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA US
Employees: 101
Phone: 17816524500
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP FAQ
Can you describe the business of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
What is the current price of FBIOP stock?
The current stock price of FBIOP is 14.42 USD. The price decreased by -0.07% in the last trading session.
Does FORTRESS BIOTECH INC - FBIO 9 3/8 PERP pay dividends?
FBIOP does not pay a dividend.
What is the ChartMill rating of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP stock?
FBIOP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for FBIOP stock?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) currently has 101 employees.
What is FORTRESS BIOTECH INC - FBIO 9 3/8 PERP worth?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a market capitalization of 464.32M USD. This makes FBIOP a Small Cap stock.
When does FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) report earnings?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) will report earnings on 2026-05-13.